Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 1, 2015, Pages

  Mosli, Mahmoud ^a,b   Samaan, Mark ^c   Nelson, Sigrid A ^d   Feagan, Brian G ^d   Travis, Simon ^e   D'Haens, Geert ^c   Sandborn, William J ^f   Zou, Gy ^d   Macdonald, John K ^d   Levesque, Barrett G ^f  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

^b KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ROBARTS RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; ENDOSCOPIC SCORING INDEX; EXPERIMENTAL DESIGN; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRAM FEASIBILITY; RELIABILITY; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ULCERATIVE COLITIS; VALIDITY;

EID: 85041860567     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011450     Document Type: Article

References (22)

1. Abraham C, Cho JH. Inflammatory bowel disease. New England Journal of Medicine 2009;361(21):2066-78.
2. Bargen JA. The management of colitis. New York: National Medical Book Company Inc, 1935.
3. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. British Medical Journal 1964;1(5375):89-92.
4. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369(9573):1641-57.
5. Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP. Outcome measurement in clinical trials for Ulcerative Colitis:towards standardisation. Trials 2007;8:17.
6. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al.A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132(2):763-86.
7. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Controlled Clinical Trials 1991;12(4 Suppl):142S-58.
8. Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964;5:437-42.
9. Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, et al.Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. New England Journal of Medicine 2005;352(24):2499-507.
10. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, et al.Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. American Journal of Gastroenterology 1993;88(8):1188-97.
11. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004;126(6):1582-92.
12. Lemann M, Galian A, Rutgeerts P, Van Heuverzwijn R, Cortot A, Viteau JM, et al.Comparison of budesonide and 5-aminosalicylic acid enemas in active distal ulcerative colitis. Alimentary Pharmacology and Therapeutics 1995;9(5):557-62.
13. Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Quarterly Journal of Medicine 1961;30:393-407.
14. Naganuma M, Ichikawa H, Inoue N, Kobayashi T, Okamoto S, Hisamatsu T, et al.Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients. Journal of Gastroenterology 2010;45(9):936-43.
15. Powell-Tuck J, Day DW, Buckell NA, Wadsworth J, Lennard-Jones JE. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Digestive Diseases and Sciences 1982;27(6):533-7.
16. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298(6666):82-6.
17. Samuel S, Bruining DH, Loftus EV Jr, Thia KT, Schroeder KW, Tremaine WJ, et al.Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clinical Gastroenterology and Hepatology 2013;11(1):49-54.
18. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. New England Journal of Medicine 1987;317(26):1625-9.
19. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, et al.5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987;92(6):1894-8.
20. Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, et al.Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012;61(4):535-42.
21. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. British Medical Journal 1955;2(4947):1041-8.
22. Zou GY. Quantifying responsiveness of quality of life measures without an external criterion. Quality of Life Research 2005;14(6):1545-52.